Most Recent
A judge has ruled that Acciona must deliver $38.6 million in bank guarantees to the entity in charge of a $511 million waste-to-energy plant in Western Australia, despite allegations of insolvency levelled by the Spanish infrastructure giant.
The corporate regulator has taken market operator ASX to court for allegedly making misleading statements about the replacement project for its CHESS share register, including that the project was on track to go live in April 2023.
Australian wine company McGuigan has lost its bid to trade mark 'Black Label' for its wine after Johnnie Walker, which makes the popular Black Label whiskey, successfully argued it would cause consumer confusion.
VCAT has found a Melbourne lawyer is not fit to practice after he sent threatening text messages to a witness in proceedings involving his former law firm.
A former EY partner who was ousted after the tax office claimed he had promoted a $700,000 tax exploitation scheme has argued he is entitled to claim privilege over communications with the accounting firm's general counsel and an external barrister, despite EY having waived it.
A personal injury firm that lost out to a class action heavyweight in a contest to run a case against Toyota unit Hino has dropped its appeal and will wear the costs it incurred in bringing its case.
Former top silk Norman O'Bryan will face court this month on charges following civil findings he engaged in a fraudulent scheme as senior counsel for the Banksia Securities class action.
A judge has rejected AFL great Phil Krakouer’s request for extensive game footage before putting on an amended claim in a racial vilification class action against the league, which is expected to bring five clubs into the proceeding.
The competition watchdog has accepted an undertaking from TPG not to renew an agreement requiring it to pre-install Google on mobile devices it supplies, following similar undertakings given by Telstra and Optus last month.
A GlaxoSmithKline unit has defeated Nova Pharmaceuticals' bid to trade mark 'Novadart' for a generic version of the British company's market-leading drug prostate drug 'Avodart', with a delegate finding the mark would cause consumer confusion.